Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sotigalimab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apexigen Announces Phase 2 Data Evaluating Sotigalimab
    Apexigen Announces Phase 2 Data Evaluating Sotigalimab

    03 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/03/2681514/0/en/Apexigen-Announces-Phase-2-Data-Evaluating-Sotigalimab-its-CD40-Agonist-Antibody-in-Combination-with-Doxorubicin-in-Patients-with-Advanced-Soft-Tissue-Sarcoma-Presented-at-the-Amer.html

    GLOBENEWSWIRE
    03 Jun 2023
    Share Share
    Apexigen Announces New Phase 2 Data Evaluating Sotigalimab at ASCO
    Apexigen Announces New Phase 2 Data Evaluating Sotigalimab at ASCO

    19 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/19/2591742/0/en/Apexigen-Announces-New-Phase-2-Data-Evaluating-Sotigalimab-its-CD40-Agonist-Antibody-at-ASCO-Gastrointestinal-Cancers-Symposium-2023.html

    GLOBENEWSWIRE
    19 Jan 2023
    Share Share
    Apexigen Presents New Data from a Ph 2 Trial its CD40 Antibody, Sotigalimab
    Apexigen Presents New Data from a Ph 2 Trial its CD40 Antibody, Sotigalimab

    10 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/10/2513554/0/en/Apexigen-Presents-New-Data-from-a-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Neoadjuvant-Chemoradiation-in-Patients-with-Resectable-Esophageal-and-G.html

    GLOBENEWSWIRE
    10 Sep 2022
    Share Share
    Apexigen Announces New Data from PII Trial Evaluating its CD40 Antibody
    Apexigen Announces New Data from PII Trial Evaluating its CD40 Antibody

    05 Sep 2022

    // PRESS RELEASE

    https://ir.apexigen.com/news-releases/news-release-details/apexigen-announces-new-data-phase-2-trial-evaluating-its-cd40-1

    PRESS RELEASE
    05 Sep 2022
    Share Share
    Apexigen Announces Nature Medicine and ASCO Presentation on PII PRINCE Trial
    Apexigen Announces Nature Medicine and ASCO Presentation on PII PRINCE Trial

    06 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/06/2456670/0/en/Apexigen-Announces-Nature-Medicine-Publication-and-ASCO-Presentation-on-the-Phase-2-PRINCE-Trial-Showcasing-Distinct-Biosignatures-in-Metastatic-Pancreatic-Cancer-Patients-Treated-.html

    GLOBENEWSWIRE
    06 Jun 2022
    Share Share
    Apexigen Shows New Data from PII Trial on Sotigalimab + Pembrolizumab in MM
    Apexigen Shows New Data from PII Trial on Sotigalimab + Pembrolizumab in MM

    12 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/12/2421457/0/en/Apexigen-Announces-New-Data-from-a-Phase-2-Trial-Evaluating-its-CD40-Antibody-Sotigalimab-in-Combination-with-Pembrolizumab-in-Patients-with-Metastatic-Melanoma-Presented-at-the-AA.html

    GLOBENEWSWIRE
    12 Apr 2022
    Share Share